Features
October 17, 2022
The NLA Announces its 2023 Educational Plan
The NLA has developed a series of educational activities and engagement opportunities for our members and those...
Read More...September 10, 2022
NLA releases: Clinical Perspective on Nutrition Interventions for Youth with Dyslipidemia
Dyslipidemia, or high cholesterol, means you have too many lipids (fat) in your blood. Nutrition interventions in youth...
Read More...September 10, 2022
NLA releases: Clinical Perspective on Assessment and Management of Statin-Associated Muscle Symptoms (SAMS)
Statin-associated muscle symptoms (SAMS) are the most common form of statin intolerance and are associated with...
Read More...August 25, 2022
NLA Endorses Newly Published 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
The NLA, the sole endorser of the new Expect Consensus Decision Pathway document and partner on the 2018 AHA/ACC/AACVPR...
Read More...June 4, 2022
NLA Release: Scientific Statement on Statin Intolerance: A New Definition and Key Considerations for ASCVD Risk Reduction in the Statin Intolerant Patient
SCOTTSDALE, Arizona. – (June 4, 2022) -- The National Lipid Association (NLA) announced the release of its official...
Read More...